Optinose cancels earnings call for Q4 and full year 2024 due to acquisition agreement

From GlobeNewswire: 2025-03-19 21:45:38

Optinose, a pharmaceutical company, has canceled its earnings conference call for the quarter and full year ended December 31, 2024, due to an acquisition agreement with Paratek Pharmaceuticals. The company will report results for the same period in a timely manner. Optinose focuses on patients treated by ear, nose, and throat (ENT) and allergy specialists. For more information, visit www.optinose.com. Contact investor relations at [email protected] or 267.521.0531.



Read more at GlobeNewswire: Optinose Cancels Fourth Quarter and Full Year 2024 Earnings